Company

ZWI Therapeutics, Inc.

ZWI Therapeutics develops novel proteins using zwitterionic polymer technology.

About

Established in 2020 and based in Massachusetts, US, ZWI Therapeutics develops novel proteins using zwitterionic polymer technology. Its polyCarboxyBetaine (pCB) polymer is designed to reduce immunogenicity and supports development of nanoparticles and hydrogels. In January 2024, the company raised USD 10 million in Series A funding from Co-win Ventures and Healthcare Partners. CEO Ed Mascioli leads the company as of 2024.

1Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in